Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking the company's fortunes. That rise was slightly more pronounced than the S&P 500 index's 2.5% increase. One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. According to reports, Merle's update was based on surveys with medical professionals indicating that the company's next-generation Journavx pain relief treatment is seeing a notable increase in demand.Continue reading

Apr 22, 2025 - 22:41

Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking the company's fortunes. That rise was slightly more pronounced than the S&P 500 index's 2.5% increase.

One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact.

According to reports, Merle's update was based on surveys with medical professionals indicating that the company's next-generation Journavx pain relief treatment is seeing a notable increase in demand.